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Background: Liver X receptor (LXR) plays a critical regulatory role in metabolism and inflammation, and has been
demonstrated to be involved in cardiovascular physiology/pathology. In the present study, we investigated the
effect of GW3965, a potent LXR agonist, on diabetic cardiomyopathy (DCM) in type 2 diabetic db/db mice.
Methods and Results: Non-diabetic db/+ mice and diabetic db/db mice received either vehicle or LXR agonist
GW3965 for 12 weeks. Systemic insulin resistance was evaluated by glucose tolerance test and homeostasis model
assessment for insulin resistance. Endpoint cardiac function was assessed by echocardiography and catheterization.
Ventricular tissue was collected for histology and gene/protein expression analysis. Untreated db/db diabetic mice
exhibited diastolic dysfunction with adverse structural remodeling (including myocardial fibrosis and increased
apoptosis). Treatment with GW3965 remarkably attenuated myocardial dysfunction and structural remodeling in
diabetic db/db mice. Mechanistically, GW3965 restored Akt phosphorylation and inhibited MAP kinases
phosphorylation, and reduced oxidative/nitrative stress and inflammation response in the diabetic myocardium.
Conclusions: Our data demonstrate that GW3965 exerts a cardioprotective effect against DCM by (at least in part)
attenuating insulin resistance, modulating Akt and MAP kinases pathways, and reducing oxidative/nitrative stress
and inflammatory response. These findings strongly suggest that LXR agonist may have therapeutic potential in
treating DCM.
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The incidence and prevalence of diabetes mellitus are
growing rapidly in societies around the world. Type 2
diabetes mellitus (T2DM) accounts for 90-95% of all diag-
nosed diabetes in adults [1]. Growing evidence has shown
that diabetes mellitus, independent from other risk factors
such as coronary artery disease and hypertension, can
affect cardiac structure and function, which supports the
existence of diabetic cardiomyopathy (DCM) [2]. As an
independent diabetic cardiac complication, DCM is
defined as diabetes-caused pathologic abnormalities in-
cluding myocardial metabolic disturbance, oxidative/nitra-
tive stress, inflammation, cardiomyocyte apoptosis, left
ventricular dysfunction and structural remodeling [3].
Although treatment for DCM including improving gly-
cemic control and restoring cardiovascular function is
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unless otherwise stated.therapeutic outcomes are far from satisfactory and the in-
cidence of diabetes-induced cardiac dysfunction continues
to escalate [3,4]. Thus, there is a great medical need to de-
velop novel pharmacological or molecular interventions to
treat left ventricular dysfunction and remodeling in DCM.
Liver X receptors (LXRs), including two different but
highly homologous LXR isoforms (LXRα and LXRβ), are
ligand-activated transcriptional factors belonging to the nu-
clear receptor superfamily [5]. LXRα is highly expressed in
metabolically active tissues, such as liver, kidney, adipose,
and intestines. LXRβ is ubiquitously expressed throughout
the body [5]. Recently, by regulating metabolic and inflam-
matory pathways, LXR has been considered as a potential
pharmacological target in the pathogenesis of cardiovascu-
lar and metabolic diseases [6]. Two synthetic LXR agonists,
GW3965 and T0901317, have been reported to prevent
atherosclerosis, inhibit inflammation, attenuate myocardial
hypertrophy, and reduce ischemia/reperfusion injury
[7-11]. Moreover, activation of LXR by T0901317 mitigates
high glucose-induced oxidative stress, and apoptosis inThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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activation to attenuate the structural and functional defects
caused by DCM in vivo have not been investigated. There-
fore, the aims of the current study were to 1) investigate
whether the LXR agonist GW3965 can protect the diabetic
heart against adverse changes using the db/db mouse
model of T2DM; and 2) clarify the downstream signaling
mediating its effect in DCM.
Materials and methods
Reagents and antibodies
Synthetic LXR ligand 3-[3-[N-(2-Chloro-3-trifluoromethyl-
benzyl)-(2,2-diphenylethyl) amino] propyloxy] phenylacetic
acid hydrochloride (GW3965) was kindly donated by Jon
Collins (GlaxoSmithKline, Research Triangle Park, NC).
Dihydroethidium (DHE) and TRIzol Reagent were from
Life Technologies (Carlsbad, CA). Mouse monoclonal
antibody against LXRα (ab41902) and rabbit polyclonal
antibody against LXRβ (ab28479) were from Abcam
(Cambridge, UK); Rabbit anti-mouse nitrotyrosine antibody
(06-284) was from Millipore (Billerica, MA); rabbit anti-
cleaved caspase-3 (5A1E, #9664), rabbit anti-nuclear fac-
tor kappa-light-chain-enhancer of activated B cell p65
(NF-κB p65, C22B4; #4764), rabbit anti-Akt (#9272),
rabbit anti-phospho-Akt (D9E, Ser473, #4060), rabbit
anti-p38 mitogen-activated protein kinase (p38 MAPK,
#9212), rabbit anti-phospho-p38 MAPK (D3F9, Thr180/
Tyr182, #4511), rabbit anti-c-Jun N-terminal kinase
(JNK, 56G8, #9258), rabbit anti-phospho-JNK (81E11,
Thr183/Tyr185, #4668), rabbit anti-Histone H3 (#9715)
and rabbit anti-glyceraldehyde-3-phosphate dehydro-
genase (GAPDH, 14C10, #2118) were from Cell Signal-
ing Technology (Beverly, MA). IRDye 800CW goat anti-
mouse (926-32210) and anti-rabbit IgG (926-32211)
secondary antibodies were from LI-COR Biosciences
(Lincoln, NE).
Animals and treatment
Experimental protocols complied with the National Insti-
tutes of Health Guidelines on the Use of Laboratory
Animals, and were approved by the Institute’s Animal Eth-
ics Committee. Male diabetic (db/db) mice and their non-
diabetic littermates (db/+) were obtained from the SLAC
Experimental Animal Center (Shanghai, China) and were
housed at 22 ± 1°C, adherent to a 12 hour light-dark cycle.
All the animals were provided with food and water ad libi-
tum. At 8 weeks of age, the db/+ and db/db mice were ran-
domized into four groups: (1) control db/+ mice (db/+); (2)
db/+ mice +GW3965 (db/+ GW); (3) db/db mice (db/db);
(4) db/db mice +GW3965 (db/db GW). The mice were
treated with GW3965 (20 mg/kg intraperitoneally) or ve-
hicle daily for 12 weeks prior to sacrifice and tissue collec-
tion. GW3965 at this dose, which was chosen based upon
our pilot study data and the published literature [11,13,14],GW3965 at this dose effectively invokes LXR activity with-
out inducing observable hemodynamic changes in animal
studies [11,13,14]. After 12 weeks, animals were subjected
to hemodynamic measurements (described below), and
hearts were excised and snap-frozen in liquid nitrogen for
biochemical determinations, or fixed in formalin for histo-
logical evaluations. At the endpoint, mice were fasted over-
night and serum samples were collected. Plasma glucose,
total cholesterol (TC), and serum triglyceride (TG) were
determined by an auto-biochemical analysis system
(Chemix-180, Sysmex, Japan).
Western blot analysis
Proteins were prepared per standard protocol, and protein
lysate concentrations were determined via Pierce BCA Pro-
tein Assay Kit (Thermo Scientific, Rockford, IL). To pre-
pare the nuclear or cytosolic fractions, protein lysate was
collected via NE-PER Nuclear Protein Extraction Kit
(Thermo Scientific). Equal quantities of proteins (30-50 μg/
lane) were subjected to 10 or 12% SDS-PAGE, dependent
upon the target proteins, electrotransferred onto nitrocellu-
lose membranes, and incubated with primary antibodies
against LXRα (1:1000), LXRβ (1:1000), cleaved caspase-3
(1:1000), NF-κB p65 (1:1000), Akt (1:1000), phospho-Akt
(1:1000), p38 MAPK (1:1000), phospho-p38 MAPK
(1:1000), JNK (1:1000) and phospho-JNK (1:1000). GAPDH
and Histone levels were utilized as loading controls for total
and nuclear protein expression, respectively. After incuba-
tion with the corresponding secondary antibodies, protein
bands were detected by an Odyssey® IR scanner (LI-COR
Biosciences, Lincoln, NE). Quantitation was performed via
Quantity One 4.4.0 software (Bio-Rad, Hercules, CA).
Real-time quantitative PCR
Total RNA was isolated from tissues with TRIzol Reagent
and purified with Qiagen’s RNeasy Mini Kit (Qiagen,
Hilden, Germany). Reverse transcription was performed by
Omniscript RT Kit (Qiagen). The resultant cDNA was
amplified by SYBR® Premix Ex Taq™ Perfect Real Time Kit
(Takara BIO, Otsu, Japan). The PCR reaction was directly
monitored by The LightCycler® 480 Real-Time PCR System
(Roche Applied Science, Indianapolis, IN). Real-time PCR
primers used were as follows: mouse LXRα (GenBank Ac-
cession No. NM001177730 and NM013839), forward 5′-
GCTCATTGCCATCAGCATC-3′ and reverse 5′-AGCAT
CCGTGGGAACATCA-3′; mouse LXRβ (GenBank Acces-
sion No. NM009473 and XM_001002072), forward 5′-TG
CCAGGGTTCTTGCAGTTG-3′ and reverse 5′-AAC
GTGATGCATTCTGTCTCGTG-3′; mouse transforming
growth factor beta1 (TGF-β1) (GenBank Accession No.
NM_011577), forward 5′-TACGGCAGTGGCTGAACCA
A-3′ and reverse 5′-CGGTTCATGTCATGGATGGTG-
3′; mouse collagen, type I, alpha 1 (collagen 1A1) (Gen-
Bank Accession No. NM_007742), forward 5′-CACCT
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CTTGGTGGTTTTG-3′; mouse nicotinamide adenine di-
nucleotide phosphate oxidase gp91phox subunit (NADPH
oxidase gp91phox subunit) (GenBank Accession No.
NM_007807), forward 5′-TGATCCTGCTGCCAGTGT
GTC-3′ and reverse 5′-GTGAGGTTCCTGTCCAGT
TGTCTTC-3′; mouse inducible nitric oxide synthase
(iNOS) (GenBank Accession No. NM_010927), forward
5′-CAAGCTGAACTTGAGCGAGGA-3′ and reverse 5′-
TTTACTCAGTGCCAGAAGCTGGA-3′; mouse GAPD
H (GenBank Accession No. BC083149), forward 5′- TGG
CACAGTCAAGGCTGAGA-3′ and reverse 5′-CTTCTG
AGTGGCAGTGATGG-3′. Real-time PCR data were rep-
resented as Ct values, defined as the crossing threshold of
PCR, obtained via LightCycler 480 Data Analysis software.
The fold change in the sample gene expression was
calculated after adjusting for GAPDH using the 2 –ΔΔCt
method [15].
Glucose Tolerance Test (GTT) and Homeostasis Model
Assessment for Insulin Resistance (HOMA-IR)
Briefly, mice were fasted overnight (14-16 h). GTT was per-
formed as described previously [16,17]. Glucose solution
was administered via an intraperitoneal injection at a dose
of 2 g/kg body weight, and the blood glucose level was
measured from tail snipping at 0, 30, 60, 90, and 120 min
after the initial glucose loading. Blood glucose level was de-
termined using a One-Touch Profile portable blood glucose
monitor (Roche, Mannheim, Germany). The area under the
curve of the glucose concentrations (AUCg) was calculated.
Serum insulin was measured by ELISA (Millipore, Billerica,
MA) [18]. HOMA-IR was calculated using the following
formula: HOMA-IR (mmol/L × μU/mL) = fasting glucose
(mmol/L) × fasting insulin (μU/mL) /22.5 [18].
In situ detection of apoptosis in heart tissue
Myocardial apoptosis was determined by terminal deoxy-
nucleotidyl transferase dUTP nick-end labeling (TUNEL)
technique via an In Situ Cell Death Detection Kit (Roche
Diagnostics) as described previously [19,20]. Results were
expressed as the percentage of apoptotic cells among the
total cell population.
Detection of caspase-3 activity in heart tissue
Cardiac caspase-3 activity was measured via caspase-3 Col-
orimetric Assay Kit (Millipore, Billerica, MA) as previously
described [15,21,22]. Briefly, 100 μg of total protein from
tissues was loaded and incubated with 25 μg Ac-DEVD-
pNA as a colorimetric-specific substrate at 37°C for
1.5 hours. Then, pNA cleaved from DEVD by caspase-3
was quantified by a microplate reader (BioTek, Winooski,
VT) at 405 nm. Changes of caspase-3 activity in db/db tis-
sue samples were calculated and compared with the meanvalue from control db/+ mice tissue. Data were expressed
as nmol pNA /h /mg protein.
Hemodynamic measurements
Left ventricular hemodynamics was evaluated after 12 weeks
by catheterization as previously described [23]. In brief, a
micromanometer-tipped catheter (1.4 F, SPR 835; Millar
Instruments, Houston, TX) was inserted through the right
carotid artery into the aorta of an anaesthetized mouse and
carefully introduced into the left ventricle (LV). The trans-
ducer was connected to a Power Laboratory system (AD
Instruments, Castle Hill, New South Wales, Australia) and
variables derived from catheterization included maximal as-
cending and descending rates of left ventricular pressure
(±dP/dt), left ventricular end-systolic pressure (LVSP), left
ventricular end-diastolic pressure (LVEDP), and heart rate.
Echocardiographic measurements
At 20 weeks of age, mice were anaesthetized with 1.5% iso-
flurane, and two-dimensional echocardiographic views of
the mid-ventricular short axis were obtained at the level of
the papillary muscle tips below the mitral valve (Vevo 770,
VisualSonic, Toronto, Canada). Variables measured on M-
mode echocardiography including LV wall thickness, LV
chamber dimensions, and systolic and diastolic function
were analyzed as described previously [24].
Sirius red staining
LV myocardial sections were stained with 0.1% picric sirius
red (Sigma-Aldrich, St Louis, MO) for fibrosis detection, as
previously described [25]. The severity of cardiac fibrosis
was evaluated after sirius red staining at 20 ×magnification
with the use of Image-pro plus 6.1 software (Media
Cybernetics, Bethesda, MD). Collagen-positive area was
normalized to the total cross-sectional area of left ventricle
and was expressed as a percentage. Areas containing blood
vessels and perivascular interstitial cells were excluded from
fibrosis quantification [26].
Measurement of oxidative stress generation in
heart tissue
Myocardial reactive oxygen species (ROS) generation was
measured by confocal microscope via in situ DHE stain or
lucigenin-enhanced chemiluminescence. For DHE stain,
unfixed frozen cross-sections (5 μm) was incubated with
DHE (5 μmol/L) at 37°C for 30 minutes in a humidified
chamber protected from light, followed by 5 minutes of
PBS washing to remove non-intercalated ethidium bromide
molecules. Images were obtained and analyzed via Leica
laser scanning confocal microscope (Leica TCS SP5 II).
NADPH oxidase activity within the heart homogenates was
measured by lucigenin-enhanced chemiluminescence via
luminometer as previously described [11,21,22]. The luci-
genin concentration in the final reaction mixture was
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tion was expressed as relative light units (RLU) per mg per
second (RLU • mg-1 • s-1).
Determination of nitrative stress generation in
heart tissue
Myocardial reactive nitrative stress (RNS) was assessed by
nitrotyrosine content, a footprint of in vivo peroxynitrite for-
mation [11,21,22], by both immunostaining and enzyme-
linked immunosorbent assay (ELISA). For immunostaining,
paraffin-embedded slices were stained with primary anti-
body against nitrotyrosine (1:100), and then immunostained
by Vectastain ABC kit (Vector Laboratories, Burlingame,
CA; 1:200). For ELISA, cardiac tissue nitrotyrosine content
was quantified by Nitrotyrosine ELISA Kit (Abnova,
Taiwan). Results were expressed as nanomoles/g protein.
Assessment of inflammatory cytokines in cardiac tissue
Tumor necrosis factor alpha (TNF-α) and interleukin 1-
beta (IL-1β) were quantified using an ELISA kit (Invitrogen,
Camarillo, CA) per manufacturer’s instructions. The tissue
supernatant fluids were added to each well, and treated
with detection antibody, supplemented with substrate and
stop solution. TNF-α and IL-1β levels were determined by
microplate reader (450 nm).
Statistical analysis
All values in the text and figures are presented as the
mean ± SEM of independent experiments from given n-
sizes. Statistical significance of multiple treatments was
determined by one-way analysis of variance (ANOVA)
followed by Tukey’s post hoc analysis using GraphPad
Prism 5 software (San Diego, California). Probabilities of
0.05 or less were considered to be statistically significant
(2-tailed).
Results
Both LXRα and LXRβ are expressed in adult heart tissue,
but LXRα is selectively upregulated by hyperglycemia in
db/db mice
Both LXRα and LXRβ subtypes were detected in cardiac
tissue, as demonstrated by both Western blot (Figure 1a)
and real-time PCR (Figure 1b). Interestingly, endogenous
LXRα protein level significantly increased in the db/db and
db/db GW group, whereas LXRβ expression remained
mostly unaffected.
LXR agonist GW3965 attenuates the phenotype of type 2
diabetes in db/db mice
We first investigated whether the activation of LXR could
suppress hyperglycemia and other metabolic abnormalities
in diabetic mice. As illustrated in Table 1, the db/db group
weighed more than the db/+ group, and demonstrated de-
rangements of serum metabolic markers such as glucose,TC and TG. Chronic treatment of 8-week-old male dia-
betic db/db mice with LXR agonist GW3965 lowered
body weight, blood glucose levels, and plasma TC levels.
However, GW3965 showed no influence on the increased
plasma TG level in diabetic mice. These findings indicate
that LXR activation by GW3965 improved the metabolic
disorders in this mouse model of T2DM.
LXR agonist GW3965 improves glucose tolerance and
insulin sensitivity in db/db mice
We next tested the effect of LXR agonist on insulin re-
sistance in db/db diabetic mice. At 20 weeks of age,
there were no statistically significant differences in the
GTT, the AUCg and HOMA-IR index between the db/+
and db/+ GW group (Figure 2). However, the levels of
GTT, AUCg, and HOMA-IR index were markedly dete-
riorated in db/db diabetic mice, which were significantly
reversed by the administration of GW3965 for 12 weeks
(Figure 2).
LXR agonist GW3965 inhibits myocardial apoptosis and
cardiac dysfunction in db/db mice
In an attempt to determine the cardioprotective role of
LXR agonist, we investigated the effects of GW3965 on
cellular apoptosis and cardiac function in type 2 diabetic
db/db mice. Our results demonstrated that compared
with the db/+ group, db/db mice clearly showed more
TUNEL-positive particles (Figure 3, a and b), increased
cleaved caspase-3 expression, enhanced caspase-3 activ-
ity (Figure 3, c and d) in cardiomyocytes, and deterio-
rated left ventricular dysfunction (Figure 4). GW3965
treatment significantly decreased cardiomyocyte apop-
tosis and improved cardiac function (Figures 3 and 4).
LXR agonist GW3965 reduces cardiac fibrosis in db/db
mice
By sirius red staining, we found that db/db mice exhib-
ited more severe cardiac fibrosis than the control group
(Figure 5, a and b). This induction of fibrosis was signifi-
cantly ameliorated after GW3965 treatment for 12 weeks
(Figure 5, a and b). Moreover, real-time PCR analysis re-
vealed significant increases in the expression of profibro-
tic genes (TGF-β1 and collagen-1A1) in diabetic hearts,
which were attenuated by GW3965 (Figure 5, c and d).
LXR agonist GW3965 attenuates myocardial oxidative
stress and nitrative stress in db/db mice
To further determine the underlying mechanisms of
LXR agonist’s protective action, we investigated the ef-
fects of GW3965 on oxidative/nitrative stress in the dia-
betic myocardium. GW3965 significantly attenuated
ROS production in db/db mice (Figure 6, a and b) and
inhibited the expression of the NADPH oxidase subunit
gp91phox (Figure 6c). Moreover, GW3965 significantly
Figure 1 LXRs expression in cardiac tissue. a-b. LXRα and LXRβ expression in cardiac tissue from db/+, db/+ GW, db/db and db/db GW mice
were determined by Western blot and real-time PCR (n =5-6). **P < 0.01 vs db/+ group. Abbreviations: GW, GW3965.
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footprint of in vivo nitrative stress, Figure 6, d and e),
and inhibited iNOS expression (Figure 6f ). Collectively,
these results demonstrate that GW3965 attenuated
diabetes-induced oxidative/nitrative stress.LXR agonist GW3965 suppresses diabetes-induced
myocardial nuclear factor-κB activation and inflammation
To investigate whether LXR agonist provided cardioprotec-
tion by inhibiting the inflammatory response in the diabetic
myocardium, we investigated the effect of GW3965 on in-
flammatory cytokine production. Protein levels of NF-κB
p65 were markedly increased in the myocardium of db/db
mice (Figure 7a). The expression of proinflammatory cyto-
kines, including TNF-α and IL-1β, was significantly aug-
mented in db/db mice (Figure 7, b and c). Furthermore,
treatment with GW3965 significantly decreased nuclear
NF-κB p65 expression and proinflammatory cytokine
(TNF-α and IL-1β) levels in db/db mice (Figure 7). TheseTable 1 GW3965 attenuated diabetes-induced metabolism ab
Group Body weight Blood gl
(g) (mmol/L
db/+ 27.84 ± 0.52 7.00 ± 0.5
db/+ GW 27.76 ± 0.60 5.30 ± 0.5
db/db 54.85 ± 0.70* 19.93 ± 1
db/db GW 45.28 ± 0.66*# 7.00 ± 0.9
Fasting blood glucose, TC, TG levels and body weight were all measured on the da
vs db/db group; n =8-10. Abbreviations: GW GW3965, TC total cholesterol, TG triglyceresults indicate that the anti-inflammatory effects of LXR
agonist contribute to cardioprotection against DCM.LXR agonist GW3965 ameliorates the impairment of insulin/
Akt signaling pathway and mitigates diabetes-induced
activation of MAP kinases
To further investigate the cellular mechanisms by which
LXR activation may attenuate diabetes-induced insulin re-
sistance and cardiac oxidative stress, we evaluated insulin/
Akt signaling and MAPK pathways, which are the most im-
portant pathways involved in insulin resistance and oxida-
tive/nitrative stress. Serine phosphorylation of Akt (serine
473) was impaired in the myocardium of db/db mice.
However, 12-week treatment with GW3965 significantly re-
stored Akt activation in db/db mice (Figure 8a). Likewise in
diabetic myocardium, an increase in the activation of p38
MAPK (Figure 8b) and JNK (Figure 8c) could be observed.
Treatment with GW3965 significantly inhibited diabetes-
induced p38 MAPK and JNK phosphorylation withoutnormalities
ucose TC TG
) (mmol/L) (mmol/L)
3 2.08 ± 0.04 0.89 ± 0.02
6 2.13 ± 0.13 0.97 ± 0.02
.56* 4.31 ± 0.15* 1.56 ± 0.04*
7# 2.91 ± 0.13*# 1.71 ± 0.04*
y of animal sacrifice. Data are means ± SEM; *P < 0.05 vs db/+ group; #P < 0.05
rides.
Figure 2 GW3965 improved glucose tolerance and insulin sensitivity in db/db mice. a-b. GTT was performed at baseline and 12 weeks after
treatment with GW3965 (n =7-9). c-d. Area under the curve of glucose levels during the GTT were also calculated (n =7-9 per group).
e. HOMA-IR index was detected (n =7-9). **P < 0.01 vs db/+ group; ##P < 0.01 vs db/db group. Abbreviations: GTT, glucose tolerance test; GW,
GW3965; HOMA-IR, homeostasis model assessment for insulin resistance.
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suggest that LXR activation alleviated DCM mainly by
modulating Akt and MAP kinases pathways in type 2
diabetes.Discussion
The major findings emanating from the current study are
as follows: (1) Both LXRα and LXRβ subtypes were
detected in adult cardiac tissue, but LXRα was selectively
upregulated by hyperglycemia; (2) GW3965 ameliorated
metabolism and improved glucose tolerance and insulin
sensitivity; (3) GW3965 protected the heart in the db/db
mouse model of type 2 diabetes from the development of
diastolic dysfunction, cell death, and cardiac fibrosis; and
(4) GW3965 also restored Akt phosphorylation and inhib-
ited MAP kinases phosphorylation, and reduced oxidative/
nitrative stress and inflammation response in the diabetic
myocardium. Taken together, these results suggest that
LXR agonist GW3965 may have great therapeutic potential
in the treatment of DCM.Originally cloned from a rat liver cDNA library and iden-
tified as an orphan nuclear hormone receptor [27], LXR is
highly expressed in the enterohepatic tissue, playing a piv-
otal role in cholesterol and lipid metabolism, glucose
homeostasis, and inflammatory response [5]. Recent evi-
dence suggests the presence of LXR in the cardiovascular
system and its significant role in cardiovascular physiology/
pathology [8-11]. In the myocardium, the expression of
LXRα was increased in streptozotocin-induced diabetic rats
[28]. LXR agonist T0901317 attenuated high glucose-
induced cardiomyocyte apoptosis in vitro [12]. However,
the role of LXR in DCM in vivo remains unknown. To the
best of our knowledge, the current study provides the first
direct evidence demonstrating that GW3965 protects cardi-
omyocytes against hyperglycemia-induced chronic adverse
changes in vivo. These data support the notion that LXR
agonist may serve as a novel therapeutic modality in the
management of DCM.
Hyperglycemia and insulin resistance have long been con-
sidered a central component in the pathogenesis of DCM
[29,30]. In insulin resistance states, impaired myocardial
Figure 3 GW3965 inhibited diabetes-induced myocardial apoptosis. a. Representative image of TUNEL immunostaining. Left panel: 20 ×
Magnification, scale bar 100 μm. Right panel: TUNEL stain of box of left panel; 40 × Magnification, scale bar 25 μm. TUNEL positive cells were
brown. b. The percentage of TUNEL positive cells was calculated. c-d. Myocardial apoptosis was determined by Western blot analysis of cleaved
caspase-3 (n =5-6) and quantification of caspase-3 activation (n =6-10). *P < 0.05 or **P < 0.01 vs db/+ group; #P < 0.05 or ##P < 0.01 vs db/db
group. Abbreviations: GW, GW3965; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; cas-3, caspase-3.
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dysfunction [31]. In addition, insulin resistance independ-
ently predicts mortality in diabetic patients with heart fail-
ure [3]. Multiple lines of evidence have indicated that LXR
is an important regulator of glucose metabolism in differ-
ent animal models of T2DM. Previous studies showed thatFigure 4 GW3965 limited diabetes-induced left ventricular dysfunction
cardiac catheterization in anesthetized mice (n =6-8). **P < 0.01 vs db/+ group
±dP/dt, maximal ascending and descending rates of LV pressure; LVSP, left ve
LVEF, left ventricular ejection fraction.pharmacologic LXR activation by GW3965 improved glu-
cose tolerance by limiting hepatic glucose output and im-
proving peripheral glucose uptake in a murine model of
diet-induced obesity and insulin resistance [32]. Moreover,
LXR agonist GW3965 reduced blood glucose concentra-
tions and improved insulin sensitivity in ob/ob mice [33].. a-f. Left ventricular function was assessed via echocardiography and
; #P < 0.05 or ##P < 0.01 vs db/db group. Abbreviations: GW, GW3965;
ntricular systolic pressure; LVEDP, left ventricular end-diastolic pressure;
Figure 5 GW3965 reduced diabetes-induced cardiac fibrosis. a. Representative image of Sirius Red-stained LV sections, 20 × Magnification.
b. Pooled data on quantification of collagen area per visual field (n =8-9). c-d. TGF-β1 and collagen 1A1 gene expression was determined by
real-time PCR. Results were normalized against GAPDH and converted to fold induction relative to db/+ mice (n =6). *P < 0.05 or **P < 0.01 vs
db/+ group; #P < 0.05 or ##P < 0.01 vs db/db group. Abbreviations: GW, GW3965; LV, left ventricle; TGF-β1, transforming growth factor beta1;
collagen 1A1, collagen, type I, alpha 1.
Figure 6 GW3965 attenuated diabetes-induced myocardial oxidative/nitrative stress. a-c. GW3965 attenuated oxidative stress in the
myocardial tissues. a. Myocardial oxidative stress was measured by confocal microscopy with in situ dihydroethidium stain (n =5-6, scale bar
25 μm). b. NADPH oxidase activity was determined by lucigenin-enhanced chemiluminescence (n =6-11). c. NADPH oxidase gp91phox gene
expression was determined by real-time PCR (n =6). Results were normalized against GAPDH and converted to fold induction relative to db/+
mice. d-f. GW3965 attenuated nitrative stress in the myocardial tissues. d. Myocardial nitrative stress was assessed via nitrotyrosine levels
determined by immunohistochemistry (n =5-6, scale bar 25 μm). e. Myocardial nitrotyrosine content was determined by ELISA analysis (n =6-11).
f. iNOS gene expression was determined by real-time PCR (n =6). Results were normalized against GAPDH and converted to fold induction
relative to db/+ mice. *P < 0.05 or **P < 0.01 vs db/+ group; #P < 0.05 or ##P < 0.01 vs db/db group. Abbreviations: GW, GW3965; RLU, relative light
units; iNOS, inducible nitric oxide synthase.
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Figure 7 GW3965 suppressed diabetes-induced inflammatory response in the myocardial tissues. a. Expression of nuclear NF-κB p65
subunit in the myocardial tissue was determined by Western blot (n =5-6). Histone level served as loading control for nuclear protein expression.
Results were normalized against histone and converted to fold induction relative to db/+ mice. b-c. TNF-α and IL-1β content in the myocardial
tissue was determined by ELISA analysis (n =6-8). **P < 0.01 vs db/+ group; #P < 0.05 or ##P < 0.01 vs db/db group. Abbreviations: GW, GW3965;
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B; TNF-α, tumor necrosis factor-α; IL-1β, interleukin-1β.
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http://www.cardiab.com/content/13/1/149The results of the present study further demonstrated that
the LXR agonist GW3965 ameliorates systemic insulin re-
sistance and myocardial dysfunction in a db/db murine
model.
Hyperglycemia and insulin resistance contribute to the
generation of excessive ROS/RNS which have damaging
effects on myocardial function. Hyperglycemia enhances
glucose oxidation and mitochondrial generation of ROS,Figure 8 GW3965 differentially regulated Akt and MAP kinases activa
expression of Akt, p38 MAPK and JNK expression in the myocardial tissues
Abbreviations: GW, GW3965; p38 MAPK, p38 mitogen-activated protein kinwhich has been implicated as a key stimulator of these
cardiac impairments [24,34,35]. Meanwhile, NO is over-
produced by activated iNOS, reacts with ROS, and turns
into the highly reactive ONOO- (RNS). ROS/RNS trigger
myocardial apoptosis, and damage the mitochondrial
membrane, leading to a “ROS-induced ROS release” vi-
cious cycle, which further worsens myocardial damage
and dysfunction [3,36]. Because of these roles of ROS/tion. a-c. Western blot analysis shows the phosphorylation and protein
(n =5-6). **P < 0.01 vs db/+ group; #P < 0.05 vs db/db group.
ase; JNK, c-Jun N- terminal kinase.
Figure 9 Proposed scheme for the cardioprotective effect of LXR agonist GW3965 against DCM. Abbreviations: MAPK, mitogen-activated
protein kinase; ROS, reactive oxygen species; RNS, reactive nitrative stress; DCM, diabetic cardiomyopathy.
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http://www.cardiab.com/content/13/1/149RNS, reducing oxidative/nitrative stress should be fa-
vored in the management of DCM. In this report, we
demonstrate that long-term administration of GW3965
significantly decreased the expression of myocardial
NADPH oxidase, as well as superoxide production and
tissue nitrotyrosine content (the footprint of in vivo
nitrative stress). Furthermore, we showed that GW3965
treatment inhibited the downstream inflammatory
response (i.e., activation of nuclear NF-κB and pro-
inflammatory cytokines) in diabetic myocardium in vivo.
Thus, inhibiting ROS/RNS and inflammatory pathways
could be an important mechanism responsible for LXR
agonist-mediated cardioprotection against DCM.
There is accumulating evidence that in the setting of
type 2 diabetes, insulin resistance and ROS/RNS may be
coconspirators in cardiac dysfunction, each capable of
triggering or worsening the other [37]. The insulin-Akt
signaling and MAPK are the most important pathways in-
volved in insulin resistance and oxidative stress [38]. It has
been demonstrated the synthetic LXR agonists amelio-
rated insulin resistance by restoring the insulin-Akt signal-
ling cascade and preventing JNK activation in adipocytes
[39,40]. In the current study, the insulin-Akt pathway was
blunted, compared with the activated MAPK pathway in
the myocardium of db/db mice. Treatment with GW3965restored Akt activation and inhibited MAP kinases phos-
phorylation in the diabetic myocardium, suggesting that dif-
ferential regulation of Akt and MAP kinases activation are
likely responsible for the aforementioned cardioprotective
effects of the LXR agonist against DCM; further studies are
warranted to define in more detail the complex mecha-
nisms involved in regulation of oxidative stress, inflamma-
tory response, and the cardioprotective effect of GW3965.
Conclusion
Our data demonstrate that the LXR agonist GW3965 ex-
erts a protective effect on DCM by (at least in part) at-
tenuating insulin resistance, modulating Akt and MAP
kinases pathways, and reducing oxidative/nitrative stress
and inflammatory response (Figure 9). LXR, therefore, is
a potentially attractive molecular target for the treatment
of DCM.
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